retatrutide weight loss retatrutide clinical trial VisualAbstract: reduces body by 17.5% in patients with obesity Experimental drug Retatrutide shows promising

This is the headline number that captures the average weight loss across the treatment group compared to placebo

A 5 mg vial dosage chart , a 5 mg/mL concentration chart , a 10 mg dosage chart , and a general compounded dose chart all provide the same fundamental information formatted for different starting points

Survodutide and orforglipron represent additional emerging molecules in this space, with orforglipron being particularly notable as an oral non-peptide GLP-1 agonist

Most insurance companies provide coverage for FDA-approved uses, reducing the out-of-pocket costs significantly, and patients using GLP-1 injections may pay as little as $25 with insurance